Arab & Middle East News
(ARABNEWSWIRE.COM, October 09, 2017 ) The Middle East and Africa Nuclear Medicine Radiopharmaceuticals Market is estimated at $495 Million in 2015 and is expected to reach $1.34 billion by 2020, growing at a CAGR of 22.11%. Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
View Full Report @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-nuclear-medicine-radiopharmaceuticals-market-134/
Increasing incidence of cancer and cardiac ailments, immense technological advancements, increasing demand for SPECT and PET applications along with the growing public awareness for healthcare are fuelling the growth of Radiopharmaceuticals market. Further, Integration of X ray tomography (CT) into SPECT have recently emerged as an excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the market. Strict regulatory framework pose a major hurdle to the translational research and clinical investigations and reimbursement issues are blocking the growth of the Radiopharmaceuticals market. In addition, short half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also restraining the Middle-East & Africa nuclear medicine Radioisotopes market.
Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-nuclear-medicine-radiopharmaceuticals-market-134/request-sample
Buy now @ https://www.marketdataforecast.com/cart/buy-now/middle-east-and-africa-nuclear-medicine-radiopharmaceuticals-market-134
• Diagnostic Radioisotopes
• Therapeutic Radioisotopes
o Beta Emitters
o Alpha Emitters
Radiopharmaceuticals market is dominated by diagnostic radioisotopes and is expected to have a market share of 90 % of the radiopharmaceuticals market while therapeutic radioisotopes contribute 10% of the market. Based on type of radioisotopes the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18,Iodine (I-123), Rubidium-82 (RB-82) and others.
The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcome of these tracers has gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.
Some of the key players influencing the Middle-East & Africa nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation,Positron Corporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
Market Data Forecast